ERBB2 and neoplasm: Bankert et al. (2011) reported that PDXs could reliably recapitulate tumor progression, ascite formation, and metastasis in the OC development process. Based on their ability to maintain heterogeneity of original tumors, PDXs were used to exploit for the response toward platinum-based chemotherapy (Ricci et al., 2014) and targeted therapies, including HER2-targeted antibodies for HER2-positive PDXs (Harris et al., 2019) and PARP inhibitors for BRCA-deficient xenografts (George et al., 2017).